| Japanese |
|---|
| Title | 99mTc-HMPAOの脳血流シンチグラフィとしての臨床的有用性の検討 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 林田孝平*, 西村恒彦*, 植原敏勇*, 今北哲*, 与小田一郎*, 岡尚嗣*, 小倉裕樹*, 林真*, 鳴尾好人**, 米川泰弘** |
|---|
| Authors(kana) | |
|---|
| Organization | *国立循環器病センター放射線診療部, **脳神経外科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 25 |
|---|
| Number | 3 |
|---|
| Page | 231-241 |
|---|
| Year/Month | 1988/3 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」21例で99mTc-HMPAOによる脳血流シンチグラフィを施行し, 基礎的および臨床的検討を行った. また123I-IMPおよび81mKr脳血流シンチグラフィと比較した. HMPAOバイアルを99mTc (<35 mCi)で標識し, 速やかに投与すれば高い脂溶性分画(>90(%))の99mTc-HMPAOが得られた. 99mTc-HMPAOの脳への摂取率は30分後に4.5(%)に達した, 脳血流シンチグラフィのSPECT像にて中大脳動脈領域の左右の分布比は初期に比し後期にて123I-IMPは高く, 99mTc-HMPAOは低かった. 前者ではいわゆる再分布, 後者では血液プールの関与が考えられた. 15例の内頸もしくは中大脳動脈の狭窄(≧90%)領域は, 99mTc-HMPAO脳血流シンチグラフィにて摂取低下として検出できた. またluxury perfusionと考えられた部位に99mTc-HMPAOの異常集積があり, 81mKrの分布によく似ていた. 99mTc-HMPAO SPECT脳血流シンチグラフィでは, 脳血流を反映した分布が得られ, 脳血流異常の評価に有用であった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Tc-99m HMPAO, Single photon emission computed tomography, Regional cerebral blood flow, Cerebral vascular disease. |
|---|
| English |
|---|
| Title | Clinical Application of Tc-99m HMPAO as Cerebral Perfusion Imaging |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Kohei HAYASHIDA*, Tsunehiko NISHIMURA*, Toshiisa UEHARA*, Satoshi IMAKITA*, Ichirou YOKOTA*, Hisashi OKA*, Hiroki OGURA*, Makoto HAYASHI*, Yoshito NARUO**, Yasuhiro YONEKAWA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department Diagnostic Radiology, **Department of Neurological Surgery, National Cardiovascular Center |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 25 |
|---|
| Number | 3 |
|---|
| Page | 231-241 |
|---|
| Year/Month | 1988/3 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] As Tc-99m d, l-hexamethylpropyleneamine oxime (HMPAO) passes through blood brain barrier and retains in brain parenchyma for several hours, this radiopharmaceutical would be an excellent regional cerebral blood flow (rCBF) tracer. In twenty-one cases of cerebral vascular disease, Tc-99m HMPAO brain single photon emission computed tomography (SPECT) was applied to detect abnormality in cerebral perfusion. The radiopharmaceutical was formed in high yield (>90%) by stannous reduction of Mo-99/Tc-99m generator elute (<35 mCi) using a kit of the ligand. Uptake rate of Tc-99m HMPAO in the brain did not change significantly during 6 hrs after post injection (p.i.). In thirteen of 17 scans (14 cases), the count ratios of hypoperfused to normal temporal area in delayed scan (3-7 hrs p.i.) were lower than those in early scan (30 min-1 hr p.i.)with Tc-99m HMPAO brain SP-ECT, however in 8 of 11 scans (10 cases) the count ratios in delayed scan were higher than those in early scan with I-123 IMP brain SPECT. These phenomena of delayed scan might be explained as decreasing activity of Tc-99m HMPAO in blood and redistribution of I-123 IMP to hypoactive area of early scan. In 15 cases of cerebral vascular disease, all of the stenotic lesions (>=90%) of major cerebral arteries were detectable as hypoactive area by Tc-99m HMPAO brain SPECT, however only 53% of the lesions were detected by brain CT as appearance of low density area. In cerebral infarction of subacute phase, "luxury Perfusion" of infarcted lesion revealed hyperactivity by Tc-99m HMPAO of which distribution was similar to that of Kr-81m. This evidence indicated Tc-99m HMPAO was a flow-related tracer and did not alter distribution during 6 hrs p.i. Tc-99m HMPAO brain SPECT is useful for detecting abnormality in cerebral blood flow. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Tc-99m HMPAO, Single photon emission computed tomography, Regional cerebral blood flow, Cerebral vascular disease. |
|---|